Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Dermatologic 1

Conditions

Pancreatic Neoplasms 1Osteosarcoma 1Neoplasms 1Melanoma 1Lymphoma 1Gastrointestinal Neoplasms 1Endocrine Gland Neoplasms 1Depressive Disorder, Major 1Depression 1Biliary Tract Neoplasms 1

Interventions

Cyclophosphamide 26Rituximab 22Biopsy 17Specimen Handling 16Prednisone 15Magnetic Resonance Spectroscopy 14Doxorubicin 14fludarabine 12Vincristine 12fludarabine phosphate 9Etoposide 7Bendamustine Hydrochloride 7Tacrolimus 6Nuclear Medicine Department, Hospital 6Melphalan 6trametinib 5acalabrutinib 5X-Rays 5Whole-Body Irradiation 5Radiotherapy 5Mycophenolic Acid 5Lenalidomide 5Crizotinib 5pembrolizumab 4ibrutinib 4copanlisib 4Prednisolone 4Mesna 4Dexamethasone 4Cytarabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma × Psilocybin × Clear all
NCT06416085 2026-03-05

Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer

University Health Network, Toronto

Phase 2 Active not recruiting
15 enrolled
DermatologicLymphoidSarcoma

Endocrine Gland Neoplasms, Lymphoma, Melanoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡